Apart from Serum, Bharat Biotech, these 5 vaccine makers are India s hope against Covid-19 businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
What Is Biological E Vaccine? Can It Be The Most ‘Affordable’ Jab? Know Here
Covid explained: Biological E is expected to produce 30 crore doses
Outlook Web Bureau 14 May 2021, Last Updated at 8:36 am Representational image Outlook Web Bureau 2021-05-14T08:34:23+05:30 What Is Biological E Vaccine? Can It Be The Most ‘Affordable’ Jab? Know Here outlookindia.com 2021-05-14T08:36:02+05:30
Also read
The Central Drugs Standard Control Organisation (CDSCO) has given permission to the Hyderabad-based pharmaceutical company Biological E Limited (BE) to start the Phase III clinical trial. In the second week of November 2020, Biological E had started the Phase I and II clinical trials of its Covid subunit vaccine candidate and has now completed them. The vaccine manufacturer will now conduct the Phase III trials of its candidate.
/
The Biden administration says it’s willing to ease up patent rules on COVID-19 vaccines to expand the global supply of the inoculations.
The goal? To narrow the massive vaccination gap between rich and poor countries. The rules won’t be immediately relaxed that will depend on unanimous agreement by all World Trade Organization members, including European nations which haven’t yet signed on.
The proposition raises many questions though, among them, whether developing countries have the infrastructure, manpower, technology and components in place to deliver vaccines quickly enough to slow the spread in their countries. There’s also concern about the future of research if intellectual property rights are weakened.
COVID vaccines: time to confront anti-vax aggression
Posted on
Nearly one billion COVID-19 vaccine doses have been delivered in less than six months, but anti-vaccine disinformation and targeted attacks on scientists are undermining progress. These threats must be confronted directly, and the authority and expertise of the health community alone aren’t enough to do this.
Efforts must expand into the realm of cyber security, law enforcement, public education and international relations. A high-level inter-agency task force reporting to the UN secretary-general could assess the full impact of anti-vaccine aggression, and propose tough, balanced measures. The task force should include experts who have tackled complex global threats such as terrorism, cyber attacks and nuclear armament, because anti-science is now approaching similar levels of peril. It is becoming increasingly clear that advancing immunization requires a counteroffensive.